# Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer

> **NCT04582981** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 136 (estimated)

## Conditions studied

- Advanced Colorectal Carcinoma

## Interventions

- **DRUG:** Fruquintinib and raltitrexed
- **DRUG:** Fruquintinib

## Key facts

- **NCT ID:** NCT04582981
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-28
- **Primary completion:** 2023-06
- **Final completion:** 2023-12
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2021-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04582981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04582981, "Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04582981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*